

# Commodity Economics Comment Free to View - Economics

### Uranium ... a counterpoint

A number of 'green' metals markets have been under significant pressure recently, dogged by oversupply concerns. Lithium and nickel prices have fallen, in particular, driving a shake-out in the markets for these products. Uranium offers a counterpoint. Similar energy-transition-related structural forces are at work, but the price cycle is at a very different stage. The price of uranium has doubled over the past year and hit a fresh 16-year high in recent weeks. Demand for uranium is rising as nuclear power gradually moves back into favour. In particular, nuclear power was included for the first time as a specific emissions-mitigation strategy in the COP agreement at COP28 in late 2023. Pledges were made to triple global nuclear power use by 2050. At the same time, supply of uranium has also been disrupted by various geopolitical factors. Prices are high and the market is tight.

Many 'green' metals markets are under pressure. We covered the lithium story recently, and there are strong echoes in the nickel market (albeit the amplitude of the price cycle is smaller (see <u>'Lithium, no</u> <u>longer stratospheric', 24 January 2024</u>). High prices and a strong medium-term structural demand motivated a significant ramp up in investment that is now delivering oversupply, which has pushed lithium and nickel prices lower. A huge ramp up in nickel production in Indonesia has been a big contributing factor to the recent boost to the supply of nickel.

For both lithium and nickel, we see the medium-term energy-transition related demand story as strong. But a shakeout for producers is underway, as the previous exuberance in these markets settles down.

Uranium is a counterpoint. Demand for uranium is also expected to be strong, and supply is tight, which is driving a significant rise in prices (see chart below). Of the 42 commodity prices tracked in the IMF global commodities index, uranium is the strongest performer over the past year.

The price of uranium is now at its highest level since early 2008. Back then too, the demand outlook was strong and supply constraints significant. In that early cycle, a major likely driver of the significant surge in prices was the flooding of a key mine in Saskatchewan, Canada, the world's largest. The price of uranium eventually surged from USD10 a pound in 2003 to USD136 a pound by its peak in 2007 (a rise of over 1200%), before sharply correcting lower. This cycle coincided with the early stages of the broader global commodity prices 'super-cycle', prior to the Global Financial Crisis in 2007/08.

The Fukushima disaster in 2011, then markedly changed the demand outlook for uranium. Japan shut down all 54 of its nuclear power plants at the time and many other countries followed suit, including Germany. Uranium prices fell sharply and for a sustained period.

Of course, this did not occur in isolation – the appearance of alternative energy sources such as shale gas in the US and a move toward greater public subsidies of renewables also likely played a part in subduing uranium prices.

This is a Free to View version of a report with the same title published on 16-January-2024. Please contact your HSBC representative or email <u>AskResearch@hsbc.com</u> for more information.

**Disclosures & Disclaimer:** This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Issuer of report: HSBC Bank Australia Limited

View HSBC Global Research at: https://www.research.hsbc.com

Paul Bloxham Chief Economist, Australia, New Zealand & Global Commodities HSBC Bank Australia Limited



From 2017, spot uranium prices were once again starting to trend higher. This followed reductions by uranium producers, in response to the market, US trade issues, and then the COVID-19 pandemic. The construction of new reactors in Asia and the Middle East gained momentum supporting demand.

The increased focus on the energy transition that came around the same time as COVID-19 pandemic, has seen renewed interest in uranium, as nuclear energy is increasingly viewed as a key part of the transition, particularly for providing base load power. At COP28, in late 2023, for example, nuclear energy was, for the first time, formally specified as one of the solutions for emissions mitigation in a COP agreement.

The structural, medium-term story that has driven demand for other critical minerals, is now playing a big role in price dynamics for uranium.

At the same time, on the supply side, prior underinvestment has seen expectations of a supply deficit grow, alongside near-term challenges including news of an expected production shortfall from the world's largest uranium supplier through 2025 (Bloomberg, 25 January 2024). This has followed ongoing supply concerns, particularly around trade with Russia, a key supplier of enriched uranium, and constrained uranium exports from Niger, following last year's military coup (Reuters, 25 January 2024).

On the supply side, the world's largest producers of uranium are Kazakhstan (43%), Canada (15%), Namibia (11%), Australia (9%) and Uzbekistan (7%). Canada's mine in Saskatchewan is the world's largest mine, at 14% of the world's supply, followed by mines in Namibia, Kazakhstan and Australia. Australia has the world's largest identified uranium reserves, accounting for 28% of the global total. These areas can expect renewed interest, given the longer term demand story.

On the demand side, the world has about 440 reactors and they provide around 10% of the world's electricity. About 60 reactors are currently under construction, according to the World Nuclear Association, with most of these in Asia (26 are in China). In addition, as a part of COP28, 22 countries combined to pledge to triple nuclear energy production by 2050.

Medium-term demand prospects for uranium are strong, which along with supply concerns, is driving another significant cyclical upswing in uranium prices.



#### 1. The price of uranium has surged, just as lithium and nickel have had corrections

Source: Bloomberg



## **Disclosure appendix**

The following analyst(s), who is(are) primarily responsible for this document, certifies(y) that the opinion(s), views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Paul Bloxham

This document has been issued by the Research Department of HSBC.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at <u>www.hsbcnet.com/research</u>.

#### Additional disclosures

- 1 This report is dated as at 16 February 2024.
- 2 All market data included in this report are dated as at close 15 February 2024, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.



### **Disclaimer**

This document has been issued by HSBC Bank Australia Limited, which has based this document on information obtained from sources it believes to be reliable but which it has not independently verified. Neither HSBC Bank Australia Limited nor any member of its group companies ("HSBC") make any guarantee, representation or warranty nor accept any responsibility or liability as to the accuracy or completeness of this document and is not responsible for errors of transmission of factual or analytical data, nor is HSBC liable for damages arising out of any person's reliance on this information. The information and opinions contained within the report are based upon publicly available information at the time of publication, represent the present judgment of HSBC and are subject to change without notice.

This document is not and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment or other investment products mentioned in it and/or to participate in any trading strategy. It does not constitute a prospectus or other offering document. Information in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on it, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

The decision and responsibility on whether or not to purchase, subscribe or sell (as applicable) must be taken by the investor. In no event will any member of the HSBC group be liable to the recipient for any direct or indirect or any other damages of any kind arising from or in connection with reliance on any information and materials herein.

Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed. Some of the statements contained in this document may be considered forward looking statements which provide current expectations or forecasts of future events. Such forward looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors.

This document is for information purposes only and may not be redistributed or passed on, directly or indirectly, to any other person, in whole or in part, for any purpose. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report, you agree to be bound by the foregoing instructions. If this report is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. The document is intended to be distributed in its entirety. Unless governing law permits otherwise, you must contact a HSBC Group member in your home jurisdiction if you wish to use HSBC Group services in effecting a transaction in any investment mentioned in this document.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document.

HSBC and/or its officers, directors and employees may have positions in any securities in companies mentioned in this document. HSBC may act as market maker or may have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell or buy securities and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented on the supervisory board or any other committee of those companies.

From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162 AFSL No. 232595). © Copyright 2024, HSBC Bank Australia Limited, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of insert issuing entity name. . MCI (P) 061/09/2023, MCI (P) 073/10/2023, MCI (P) 007/10/2023, MCI (P) 008/01/2024